Blue Trust Inc’s iTeos Therapeutics ITOS Stock Holding History

Blue Trust Inc’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-116	Closed	-$1.72K	–	2709
2024 Q3	$1.72K	Buy	+116	New	+$1.77K	﹤0.01%	2608

Other funds holding ITOS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Blue Trust Inc's ITOS Position: Q4 2024 in Review

Blue Trust Inc sold out of iTeos Therapeutics (ITOS) in Q4 2024, closing a stake of 116 shares — an estimated $1.72K sold.

Blue Trust Inc first reported a position in ITOS in Q3 2024 and held it in 1 quarter. The position peaked at $1.72K in Q3 2024. 136 funds tracked by Wall St. Rank hold ITOS as of Q4 2024.

Blue Trust Inc reported no remaining iTeos Therapeutics position as of Q4 2024 after selling out during the quarter.
Blue Trust Inc sold 116 iTeos Therapeutics shares in Q4 2024, an estimated $1.72K.
Blue Trust Inc first reported a position in iTeos Therapeutics in Q3 2024 and held it in 1 quarter.
Blue Trust Inc's iTeos Therapeutics position peaked at $1.72K in Q3 2024.
136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2024.

Based on Blue Trust Inc's 13F filing for Q4 2024, filed 22 Jan 2025.